Embed Size (px)
Citation preview
www.dgnn-conference.de
60th
Annual Meeting of the German Society for Neuropathology and Neuroanatomy (DGNN)
ProGram
26–28 August BERLIN 2015 Germany
© fo
tolia
.com
/kts
desi
gn
Organisation and Imprint
Venue DateKaiserin-Friedrich-Haus 26–28 August 2015Robert-Koch-Platz 7 10115 Berlin/DEwww.kaiserin-friedrich-stiftung.de
Conference Websitewww.dgnn-conference.de
Hosting societyGerman Society for Neuropathology andNeuroanatomy (DGNN)www.dgnn.de
Conference ChairProf. Dr. med. Frank HeppnerDepartment of NeuropathologyCharité – Universitätsmedizin BerlinCampus Charité MitteCharitéplatz 110117 Berlin/DE
Conference languageThe official conference language is English.
Publishing of AbstractsAbstracts are published via the online portal German Medical Science (GMS).
Congress Organisation and Industrial ExhibitionConventus Congressmanagement & Marketing GmbHUlrike EisnerCarl-Pulfrich-Straße 1 07745 Jena/DEPhone +49 3641 31 16-368Fax +49 3641 31 [email protected] • www.conventus.de
General Information
Registration FeesRegular 220 EURStudent* 110 EUR
Workshop (limited places – first come, first served)26 August 2015 50 EUR
Social ProgramSocial Dinner27 August 2015Regular 60 EURStudent* 35 EUR
Guided Tour through the Charité Campus Mitte26 August 2015 6 EURGuided City Tour along the Berlin Wall28 August 2015 12 EUR
* Please provide proof via email [email protected] and quote DGNN or fax +49 3641 31 16-244.
Please find the actual general terms and conditions at the conference website: www.dgnn-conference.de.
Check-InThe Check-In desk will be located in the foyer on the first floor.
Speakers’ Desk Speakers are requested to submit their slides at least 90 minutes before their presentations at the speakers’ desk in the back of the lecture hall.
Industrial ExhibitionThere is an accompanying industrial exhibition. The exhibitors are looking forward to welcoming you and to present their comprehensive range of innovative products.
General Information
CertificationThe DGNN 2015 has been acknowledged for certification (CME cred-its) of the Scientific and Teaching Program at the Berlin Chamber of Physicians.
Scientific ProgramWorkshop, 26 August 2015 4 Points, Category C26 August 2015 3 Points, Category B27 August 2015 6 Points, Category B28 August 2015 6 Points, Category B
Daily registration at the certification desk of the “LAK” (near Check-In) is a mandatory requirement! Your name badge will contain an individual barcode. For certification, we kindly ask you to scan your name badge as well as your EFN-barcode once a day at the certifica-tion desk. Here, you will also receive your daily certificate for your Medical Chamber.
Opening Hours 26 August 27 August 28 AugustIndustrial Exhibition 1100–1830 0800–1900 0800–1630
Poster Exhibition 0800–1900 0800–1630
Check-In 0900–1830 0830–1900 0800–1600
Speakers’ Desk 0900–1830 0830–1900 0800–1600
CateringCatering will be provided during the official program breaks in the industrial exhibition.
InternetThe Kaiserin-Friedrich-Haus will provide a free Wifi access. Login data:Net: HörsaalCode: hoersaal10115
People with disabilities:There will be no barrier-free access to the venue. People with dis-abilities are kindly requested to contact Conventus.
Sponsors and Exhibitors
We would like to thank the following exhibitors and sponsors for their great support of the 60th Annual Meeting of the German Society for Neuropathology and Neuroanatomy:
Gold SponsorGenzyme GmbH (Neu-Isenburg/DE)
Silver SponsorTeva Pharma GmbH (Ulm/DE)
Bronze SponsorBiogen Idec (Ismaning/DE)
SponsorRoche Diagnostics (Mannheim/DE)
ExhibitorsBioLegend (London/GB)
Bundesverband Deutscher Pathologen e. V. (Berlin/DE)
Charles River, Research Models and ServicesGermany GmbH (Sulzfeld/DE)
GRIFOLS Deutschland GmbH (Frankfurt/DE)
Meso Scale Discovery (Rockville, MD/US)
NanoString Technologies Germany GmbH (Hamburg/DE)
Novartis Pharma GmbH (Nürnberg/DE)
Olympus Deutschland GmbH – Mikroskopie (Hamburg/DE)
Thermo Fisher Scientific GmbH (Dreieich/DE)
Vmscope GmbH (Berlin/DE)
Media CooperationsDustri-Verlag Dr. Karl Feistle GmbH & Co. KG (Oberhaching, München/DE)Clinical Neuropathology
State: 30 July 2015
C.P. Panteliadis
2011. XV, 312 pages,98 figures, 15 in colour,19 tables, 16 x 24 cm, hardcover, ISBN 978-3-87185-403-3US$ 85.00 / Euro 65.00+ shipping
D.K. StavrouC. Hagel
2010. XIV, 232 pages,24 figures, 14 in colour,11 tables,16 x 24 cm, hardcover,ISBN 978-3-87185-401-9US$ 65.00 / Euro 50.00+ shipping
Immune Biologyof Brain Tumours
Cerebral Palsy
Topics:Definition – epidemiology – neuropathology – prevention – clinicalcharacteristics – diagnosis – treatment (physiotherapy, orthopedicmanagement, surgery, medication) – comorbidities – prognosis
Topics:Introduction – general considerations – brain tumour immunology –glioma-associated antigens – radioimmunoscintigraphy of gliomas –applications of monoclonal antibodies in clinical neurooncology
Neurology – Oncology – Paediatrics
Dustri-Verlag Dr. Karl Feistle
Dustri-Verlag Dr. Karl Feistle GmbH & Co. KGBajuwarenring 4D-82041 Oberhaching, DeutschlandPhone: +49 89 613 86 1-0Fax: +49 89 613 54 12
0
5
25
75
95
100
dgnn_2015_s
Mittwoch, 8. Juli 2015 11:48:17
Copaxone® 20 mg/ml Injektionslösung in einer Fertig-spritze; Copaxone® 40 mg/ml Injektionslösung in einer FertigspritzeWirkstoff: Glatirameracetat. Zusammensetzung: 1 ml Injektionslsg. enth. 20 mg; 40 mg Glatirameracetat*, entspr. 18 mg; 36 mg Glatiramer pro Fertigspritze. *Gla-tirameracetat ist d. Acetatsalz v. synth. Polypeptiden, die 4 natürl. vork. Aminosäuren enth.: L-Glutaminsäure, L-Alanin, L-Tyrosin und L-Lysin. Die Spannen d. Molar-fraktionen betrag. 0,129 - 0,153; 0,392 - 0,462; 0,086 - 0,100 bzw. 0,300 - 0,374. Das durchschn. Molekulargew. v. Glatirameracetat liegt i. Ber. v. 5000 bis 9000 Dalton. Sonst. Bestandt.: Mannitol (Ph.Eur.) Wasser f. Injektionszw. Anwend.gebiete: -20 mg/ml: Behandl. v. Pat. mit e. klar def. ersten klein. Episode u. hohem Risiko, eine klein. gesich. Multiple Sklerose (MS) zu entwickeln. Redukt. d. Schubfreq. b. ambul. Pat. mit schubförm. remitt. MS (RRMS). In klein. Studien war dies gekennzeichn. durch mind. 2 Schübe mit neurolog. Funk-tionsstörgn. währ. d. letzt. 2 Jahre. -40 mg/ml: Behandl. der schubförm. MS (RMS). Copaxone® ist nicht ind. bei prim. o. sek. progred. MS. Geg.anz.: Überempf. gg. den Wirkstoff od. einen der sonst. Bestandt., Schwan-gerschaft. Schwangerschaft/Stillzeit: Kontraind. währ. d. Schwangerschaft. Vorsicht b. Gabe an stillende Müt-ter. Nebenw.: Reakt. a. d. Inj.stelle: Erythem, Schmerz, Quaddelbildung, Pruritus, Ödem, Entz. u. Überempf.. Post-Inj.-Reakt. (mind. eines d. folg. Sympt.): Gefäßerwei-terung, Brustschm., Dyspnoe, Herzklopfen od. Tachykar-die. Sehr häufig: Infektionen, Influenza, Angst, Depressi-on, Kopfschm., Vasodilatation, Dyspnoe, Übelkeit, Rash, Arthralgie, Rückenschm., Asthenie, Brustschm., Reakt. a. d. Injekt.stelle, Schmerz. Häufig: Bronchitis, Gastroenteri-tis, Herpes simplex, Otitis media, Rhinitis, Zahnabszess, vag. Candidamykose, benign. Hautneoplasma, Neo-plasma, Lymphadenopathie, Überempf.reakt., Anorexie, Gewichtszun., Nervosität, Dysgeusie, erh. Muskeltonus, Migräne, Sprachstör., Synkope, Tremor, Diplopie, Funk-tionsstör. d. Augen, Funktionsstör. d. Ohren, Palpitatio-nen, Tachykardie, Husten, saisonale Rhinitis, anorekt. Funktionsstör., Obstipation, Zahnkaries, Dyspepsie, Dys-phagie, Darminkontinenz, Erbrechen, abnormer Leber-funktionstest, Ekchymose, Hyperhidrose, Pruritus, Stör. d. Haut, Urtikaria, Nackenschm., Harndrang, Pollakisurie, Harnretention, Schüttelfrost, Gesichtsödem, Atrophie a. d. Injekt.stelle einschl. lokalisierter Lipodystrophie , lok. Reakt., peripheres Ödem, Ödem, Pyrexie. Gelegentl.: Abszess, Zellulitis, Furunkel, Herpes zoster, Pyelonephri-
tis, Hautkrebs, Leukozytose, Leukopenie, Splenomegalie, Thrombozytopenie, abnorme Lymphozyten-Morphologie, Struma, Hyperthyreose, Alkoholintol., Gicht, Hyperlipidä-mie, erh. Blutnatrium, verr. Serumferritin, abnorme Träume, Verwirrth., Euphorie, Halluzinationen, Feindseligkeit, Ma-nie, Persönlichkeitsstör., Suizidversuch, Karpaltunnelsyn-drom, kognitive Stör., Konvulsion, Dysgraphie, Dyslexie, Dystonie, motor. Stör., Myoklonus, Neuritis, neuromusk. Blockade, Nystagmus, Lähmung, Peroneuslähmung, Stu-por, Gesichtsfeldstör., Katarakt, Schädigung d. Hornhaut, trock. Auge, Augenblutung, Ptosis, Mydriasis, Optikusa-trophie, Extrasystolen, Sinusbradykardie, paroxysmale Tachykardie, Krampfadern, Apnoe, Nasenbluten, Hy-perventilation, Laryngospasmus, Funktionsstör. d. Lunge, Gefühl d. Erstickens, Kolitis, Dickdarmpolypen, Enteroko-litis, Aufstoßen, ösophageales Geschwür, Parodontitis, rekt. Blutung, Vergröß. d. Speicheldrüse, Cholelithiasis, Hepatomegalie, Angioödem, Kontaktdermatitis, Erythe-ma nodosum, Hautknötchen, Arthritis, Bursitis, Flanken-schm., Muskelatrophie, Osteoarthritis, Hämaturie, Ne-phrolithiasis, Harnwegserkrank., Harnanomalie, Abort, Brustschwellung, Erektionsstör., Beckenvorfall, Priapismus, Funktionsstör. d. Prostata, anorm. Zervixabstrich, Stör. d. Testis, Vaginalblut., Stör. v. Vulva u. Vagina, Zyste, Kater-gefühl, allg. Unterkühlung, unmittelbare Post-Injekt.-Reakt., Entzündg., Nekrose a.d. Injekt.stelle, Schleimhautstör., Post-Impfungs-Syndr.. Selt. Berichte v. anaphylakt. Reakt. b.m. Copaxone behand. MS-Pat. stammen aus nicht kon-tr. klin. Studien u. aus d. Erfahrungen nach Markteinfüh-rung. Weitere Inform. entnehmen Sie bitte d. Fachinfo.. Wechselwirkungen: Kortikosteroide. Dosierung: -20 mg/ml.: Erw.: 20 mg Glatirameracetat (entspr. einer Fer-tigspritze) als einmal tg. subkutane Injektion. -40 mg/ml: Erw.: 40 mg Glatirameracetat (entspr. einer Fertigspritze), angewendet als dreimal wöchentl. subkutane Injektion im Abstand von mind. 48 Std. Es wurden keine prosp., random., kontroll. klin. Studien od. Untersuchungen zur Pharmakokinetik bei Kdrn. u. Jugendl. durchgeführt. Die in begrenzt. Umfang veröffentl. Daten weisen jedoch darauf hin, dass d. Sicherheitsprofil bei Jugendl. von 12 bis 18 J., die tgl. 20 mg Copaxone s.c. erhalten, mit dem von Erw. vergleichbar ist. Zur Anwend. von Copaxone bei Kdrn. und Jugendl. unter 12 J. (-20 mg/ml) bzw. unter 18 J. (-40 mg/ml) liegen nicht genüg. Daten vor, um eine Empf. z. Anwend. geben zu können. Daher bei dieser Pat.-gruppe nicht anwenden. Verschreibungspflichtig. Stand: Zulassungsinhaber: Teva Pharma GmbH, Graf-Arco-Str. 3, 89079 Ulm. Januar 2015
Bei schubförmiger MS:
aktiv leBen.geStern. heute. Morgen. JETZT
WÖCHENTL ICH
Welcome Note of the Conference Chair
Dear colleagues, guests and friends,
It is my great pleasure to welcome you to the 60th Annual Meeting of the German Society for Neuropathology and Neuroanatomy (DGNN)at the Kaiserin-Friedrich-Haus, very nearby the historical campus of the Charité – Universitätsmedizin Berlin, right at the center of Berlin. As an ideal location for scientific exchange and training of young as well as experienced scientists and physicians, we hope for numerous participation and interesting contributions.
The meeting will cover the broad spectrum of diagnostic and experi-mental neuropathology comprising the areas neurodegeneration, neu-rooncology, myopathology and neuroinflammation/neuroimmunology. Various emerging neuroscience topics will be presented and intensely discussed, e. g. within panel discussions, by outstanding international leaders in the field. In order to meet the interests of all participating groups including young researchers, the program will be further com-pleted by poster presentations (“data blitz”) and workshops.
We are looking forward to an exciting meeting!
Frank Heppner, M. D. Director, Department of Neuropathology Congress President DGNN Meeting 2015
Scientific Program • Wednesday, 26 August 2015
0900–1200 DGNN WorkshopSeminarraum 0900 Neuropathologische Diagnostik von Hirntumoren – alte und neue Herausforderungen Werner Paulus (Münster/DE)1000 Myopathologie der Myositiden Werner Stenzel (Berlin/DE) Hans-Hilmar Goebel (Berlin/DE)1100 Neurodegenerative Erkrankungen: neuropathologische Diagnose und Staging am Beispiel von M. Alzheimer und Frontotemporalen Demenzen Manuela Neumann (Tübingen/DE) Dietmar Thal (Ulm/DE)
1400–1500 Opening CeremonyHörsaalChair F. Heppner 1400 Welcome Axel Radlach Pries, Dean of the Charité (Berlin/DE) Frank Heppner, Congress President (Berlin/DE)1410 Potential role of extracellular tau in development and spread of tauopathy effects of anti-tau antibodies David Holtzman (St. Louis, MO/US)
1500–1640 Neurodegeneration IHörsaalChairs M. Neumann/D. Thal 1500 Tau signatures in familial prion diseases and FTDP-17 MAPT Bernardino Ghetti (Indianapolis, IN/US)1530 Activation of resident brain microglia by viralND 6 infection leads to transient clearance of infectious prions from the brain Susanne Krasemann (Hamburg/DE)1540 In vivo imaging of presynaptic pathology in a mouseND 8 model of Alzheimer’s disease Mario Dorostkar (München/DE)1550 ER chaperone Sigma 1 receptors (SigR1) in theND 5 pathogenesis of amyotrophic lateral sclerosis (ALS) and Huntington’s disease (HD) Anand Goswami (Aachen/DE)
Scientific Program • Wednesday, 26 August 2015
1600 Integrated analysis of the epigenome inND 1 Alzheimer’s disease brains and during ageing Theo Franz Josef Kraus (München/DE)1610 Brain infarction, dementia, and related vesselND 2 disorders – impact of infarct size, distribution, and its association with vessel and heart disorders Moritz Hecht (Ulm/DE)1620 Phosphorylated α-synuclein in skin nerve fibersND 3 differentiates Parkinson´s disease from multiple system atrophy Leonora Zange (Berlin/DE)1630 Insights in aggregation behaviour and lipidmembraneND 4 interaction potential of mutants of alpha-synuclein in vitro Viktoria Ruf (München/DE)
1640–1710 Coffee Break and Industrial Exhibition
1710–1750 Neurodegeneration IIHörsaalChairs C. Mawrin/F. Heppner 1710 Prion-like propagation of synucleinopathy in miceND 7 expressing wild-type alpha-synuclein Gültekin Tamgüney (Bonn/DE)1720 Towards development of new therapeutics for synucleinopathies in preclinical models Eliezer Masliah (San Diego, CA/US)
1750–1830 Open Topic IHörsaalChairs C. Mawrin/F. Heppner 1750 High-pressure freezing for EM to study plasticityOT 1 and pathology of identified central synapses Michael Frotscher (Hamburg/DE)1800 News and views on mitochondrial encephalomyopathies Hannes Vogel (Stanford, CA/US)
1845–2045 DGNN Society MeetingHörsaal
Scientific Program • Thursday, 27 August 2015
0830–1020 Neurooncology IHörsaalChairs G. Reifenberger/A. Koch 0830 Experimental models of brain metastasis and new therapeutic approaches Rolf Bjerkvig (Bergen/NO)0900 Molecular classification of brain tumors Stefan Pfister (Heidelberg/DE)0930 A mouse model for Embryonal Tumors NO 1 with NO 1 Multilayered Rosettes (ETMRs) predicts tumor responsiveness to Sonic hedgehog inhibitors Julia Pöschl (München/DE)0940 Histopathological WHO grading and H3.3K27NO 2 mutational status represent independent prognostic markers in pediatric high grade gliomas Torsten Pietsch (Bonn/DE)0950 CD74 expression in tumour cells is a positiveNO 7 prognostic marker for brain metastases patients Pia S. Zeiner (Frankfurt a. M./DE)1000 DNA methylation array-based molecular 4profilingNO 4 for brain tumour classification David Capper (Heidelberg/DE)1010 Papillary tumor of the pineal region – a distinctNO 6 molecular entity Stephanie Heim (Münster/DE)
1020–1040 Open Topic IIHörsaalChairs G. Reifenberger/A. Koch 1540 SIGMA1Receptor of mice and menOT 2 Hamid Azzedine (Aachen/DE)1550 Claudin-3 maintains bloodbrain barrier and delaysOT 3 recovery from stroke Ingolf Blasig (Berlin/DE)
1040–1100 Coffee Break and Industrial Exhibition
1100–1200 Poster Session ISeminarraum/Clubraum
1200–1230 Poster Flash IHörsaal
Scientific Program • Thursday, 27 August 2015
1230–1330 Lunch Break and Industrial Exhibition
1330–1540 MyopathologyHörsaalChairs J. Weis/W. Stenzel1330 Modern molecular genetics in diagnostic myology Markus Schülke (Berlin/DE)1400 Specific auto-antibodies in inflammatory myopathies lead to the identification of new clinico pathological syndromes Olivier Benveniste (Paris/FR)1430 Neurodevelopmental, neurodegenerative and neuromuscular disorders due to defects in cellular trafficking and autophagy Karl-Heinz Jungbluth (London/GB)1500 The spectrum of glycogen storage diseases – How essential is a muscle biopsy? Benedikt Schoser (München/DE)1530 Proteasome immunosubunits in the pathogenesisM1 of myopathies Salyan Bhattarai (Berlin/DE)
1540–1610 Coffee Break and Industrial Exhibition
1610–1750 Neuroinflammation/Neuroimmunology IHörsaalChairs T. Kuhlmann/C. Stadelmann-Nessler1610 Contributions of innate immune activation to neurodegeneration in Alzheimer’s disease Michael Heneka (Bonn/DE)1640 Vascular Determinants of Lesion Formation in Multiple Sclerosis Alexandre Prat (Montréal/CA)1710 Pathologic mechanims of disease progression in multiple sclerosis Wolfgang Brück (Göttingen/DE)1740 Fluorescence lifetime imaging reveals oxidativeNI 1 stress mechanisms in chronic neuroinflammation Helena Radbruch (Berlin/DE)
1750–1810 Coffee Break and Industrial Exhibition
Scientific Program • Thursday, 27 August 2015
1810–1850 Neuroinflammation/Neuroimmunology IIHörsaalChairs W. Brück/I. Blümcke1810 Temporal modulation of the immunomodulatoryNI 2 surface molecule CD47 is a precondition for remyelination in MS lesions Andreas Junker (Göttingen/DE) 1820 Pathological features of steroid mitigated CNSNI 3 lymphoma mimicking inflammatory demyelination Alonso Barrantes-Freer (Göttingen/DE)1830 Host microbiota constantly control maturation andNI 4 function of microglia in the central nervous system Daniel Erny (Freiburg/DE)1840 Microglia regulate adult-born neuroblastNI 5 development and survival Frank Heppner (Berlin/DE)
Scientific Program • Friday, 28 August 2015
0800–0930 Panel Discussion – BiobankingHörsaalModerator J. Weis0800 Kick-off presentation Neuropathology of atypical parkinsonism in The Mayo Clinic Brain Bank for Neurodegenerative Disorders Dennis W. Dickson (Jacksonville, FL/US)Participants D. Dickson, M. Neumann, D. Thal and others
0930–1000 Coffee Break and Industrial Exhibition
1000–1100 Poster Session IISeminarraum/Clubraum
1100–1130 Poster Flash II
1130–1230 Lunch Break and Industrial ExhibitionHörsaal
1230–1350 Neurooncology IIHörsaalChairs W. Paulus/A. Pagenstecher1230 Angiogenesis in neurooncology – from hero to zero, and about the challenge to come back Peter Vajkoczy (Berlin/DE)1300 Employing biomarkers in the treatment of brain tumors Wolfgang Wick (Heidelberg/DE)1330 Improved prognostic stratification of patients withNO 5 diffuse cerebral WHO grade II and III gliomas using genome- and transcriptome-wide molecular profiling Guido Reifenberger (Düsseldorf/DE)1340 Next-Generation-Sequencing in routineNO 3 neuropathology diagnostics Felix Sahm (Heidelberg/DE)
1350–1520 Panel Discussion – (Neuro)oncology andHörsaal Personalised MedicineModerator P. Vajkoczy 1350 Kick-off presentation The Network Genomic Medicine – lung cancer challenges and limitations of NGS-based cancer diagnostics Reinhard Büttner (Köln/DE)Participants R. Büttner, W. Wick, S. Pfister and others
Scientific Program • Friday, 28 August 2015
1520–1630 Award and Closing CeremonyHörsaal
The following awards will be granted during the Closing Ceremony:
Theodor-Schwann Prize (Laudatio: J. Weis) Werner-Rosenthal Prize (Laudatio: W. Paulus) Assmus Prize (Laudatio W. Brück)
General Information for Authors and Presenters
All posters will be presented during the Poster Sessions.
Posters referring to the topics• Neurodegeneration (ND)• Neuroinflammation (NI)will be presented on Thursday, 27 August 2015, from 1100–1200.
Posters referring to the topics• Myopathology (M)• Neurooncology (NO)• Free Topics (OT)will be presented on Friday, 28 August 2015, from 1000–1100.
After the Poster Sessions, selected authors will be given the oppor-tunity to present their poster during the Poster Flashes following the Poster Sessions.
Poster presenters are asked to be present during the poster sessions.
All authors and titles of the posters are listed in the abstract volume that is available at http://www.egms.de/en/meetings/dgnn2015/index.htm.
Save the date!
2016
JOINT-MEETING of theGERMAN SOCIETY for NEUROPATHOLOGY and NEUROANATOMY (DGNN) and THE SCANDINAVIAN NEUROPATHOLOGICAL SOCIETY (SNS)
www.dgnn-conference.de
22–24 September HAMBURG Germany
